Skip to content

Post-operative analgesic effects of an oral cannabinoid

Post-operative analgesic effects of an oral cannabinoid: an efficacy and dose-response randomised controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN05531690
Enrollment
152
Registered
2006-02-24
Start date
2003-10-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-operative pain (in major orthopaedic, gynaecologic, abdominal and plastic procedures) Signs and Symptoms Post-operative pain

Interventions

Group A: 1 mg nabilone, one capsule of 1 mg + one capsule of placebo, 8 hourly Group B: 2 mg nabilone, two capsules of 1 mg, 8 hourly Group C: 50 mg ketoprofen, one capsule of 50 mg + one capsule of p

Sponsors

Hôtel-Dieu de Montréal (Canada)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients 18 - 75 years old, either sex, scheduled for major orthopaedic surgery 2. Patients using a morphine patient controlled analgesia (PCA) device post-operatively 3. Patients should be American society of Anaesthesiology (ASA) pre-operative status I, II or III 4. Patients willing and able to give written informed consent

Exclusion criteria

Exclusion criteria: 1. Patients using cannabis or other substance of abuse, alcoholism 2. Patients where morphine is not the drug of choice for PCA 3. Patients with planned concomitant medication during the study with any of the following: non-steroidal anti-inflammatory drugs, acetaminophen, more than 300 mg acetyl salicylic acid per day, sedatives, anticonvulsants, antidepressants 4. Patients with ischaemic heart disease, cardiac arrhythmias failure 5. Patients with history of gastric or duodenal ulcer, renal insufficiency or asthma 6. Patients with chronic pain conditions and/or patients receiving chronic opioid therapy 7. Patients with history of psychiatric illness 8. Pregnant or lactating women

Design outcomes

Primary

MeasureTime frame
A total (24 hours) morphine Patient Controlled Analgesia (PCA) consumption hours.

Secondary

MeasureTime frame
1. Pain intensity as measured by the Visual Analogue Scale (VAS) 2. Anti-emetic properties of nabilone 3. Assessment of mood and anxiety prior to surgery 4. Time to discharge criteria as indices of post-operative recovery 5. Quality of sleep 6. Incidence of side effects such as sedation, euphoria ('high'), psychotic episodes

Countries

Canada

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026